At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
bortezomib +2 moredrug
Likely dose
bortezomib 1.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating bortezomib, bendamustine, and 1 other intervention for Non-Hodgkin's Lymphoma. Completed, enrolled 31 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc., Cephalon
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionJun 2009
Study CompletionOct 2009
TodayJul 2026
First PostedOct 22, 2007
Enrollment StartOct 1, 2007
Primary CompletionJun 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.7 years ago
Interventions
bortezomibdrug
1.3 mg/m\^2 on days 1, 4, 8, 11
bendamustinedrug
90 mg/m\^2 days 1 and 4
rituximabdrug
375 mg/m\^2 day 1